This week we have seen decent sized inflows in the largest Biotech Equity based ETP in the U.S. listed landscape, IBB (iShares NASDAQ Biotechnology, Expense Ratio 0.48%), to the tune of about $400 million. Net year to date the fund has reeled in north of $1.2 billion now, pushing the fund near the...